Tardive akathisia due to sulpiride.

abstract：:A patient with melanoma and sporadic positive melanuria developed Parkinson's disease. Treatment with levodopa failed to modify tumoral progress. However, during chemotherapy with dacarbazine, the patient experienced a significant impairment to levodopa response. ...

journal_title：Clinical neuropharmacology

authors： Merello M,Esteguy M,Perazzo F,Leiguarda R

更新日期：1992-02-01 00:00:00

abstract：:Botulinum toxin A (BTA) is considered an effective treatment of cervical dystonia. The aim of this prospective, randomized, double-blind study was to compare Botox and Prosigne, a BTA of Chinese origin, with a view to establish the safety, the efficacy, and the equivalence of doses of the 2 formulations in the treatme...

journal_title：Clinical neuropharmacology

authors： Quagliato EM,Carelli EF,Viana MA

更新日期：2010-01-01 00:00:00

abstract：:A large number of patients with neurosyphilis present dementia with a progressive course and psychiatric symptoms such as depression, mania, and psychosis. Despite prompt and proper antibiotic treatment, the recovery is often incomplete, especially when tissue damage has occurred. We reported a patient with persisted ...

journal_title：Clinical neuropharmacology

authors： Wu YS,Lane HY,Lin CH

更新日期：2015-07-01 00:00:00

abstract：BACKGROUND:Topiramate (TPM) is a fructose derivative, which was originally developed as an antiepileptic. In this context, movement disorders (MDs) are possible adverse events secondary to TPM. CASE REPORTS:Two patients (cases 1 and 2) developed myoclonus, and the other 2 had restless leg syndrome (RLS, cases 3 and 4)...

journal_title：Clinical neuropharmacology

authors： Rissardo JP,Caprara ALF

更新日期：2020-07-01 00:00:00

abstract：:To evaluate the efficacy and safety of gabapentin in the treatment of muscle cramps, we engaged an open-label trial with a group of 30 patients with frequent (> 5 cramps/week), stable, long-lasting cramps, associated with different diseases. Gabapentin was effective in reducing the frequency and severity of muscle cra...

journal_title：Clinical neuropharmacology

authors： Serrao M,Rossi P,Cardinali P,Valente G,Parisi L,Pierelli F

更新日期：2000-01-01 00:00:00

abstract：:Duloxetine is a serotonin-noradrenaline reuptake inhibitor that is effective in the treatment of major depressive disorder (MDD) and chronic pain. The safety of duloxetine has been shown by many previous studies. We report a patient who experienced visual hallucinations after taking duloxetine. The patient experienced...

journal_title：Clinical neuropharmacology

authors： Tomita T,Yasui-Furukori N,Kaneko S

更新日期：2013-09-01 00:00:00

abstract：:The extensive use of the Unified Parkinson's Disease Rating Scale (UPDRS) has revealed low interrater reliability in some items and redundancy in others. In view of these shortcomings, we have structured a new scale that includes a zero-to three-point scale for each item in the evaluation of PD. The mental axis includ...

journal_title：Clinical neuropharmacology

authors： Rabey JM,Bass H,Bonuccelli U,Brooks D,Klotz P,Korczyn AD,Kraus P,Martinez-Martin P,Morrish P,Van Sauten W,Van Hilten B

更新日期：1997-08-01 00:00:00

abstract：:A significant proportion of the interindividual variance in human fatness is attributable to genetic factors. This fact is indicated (inter alia) by studies of identical twins demonstrating that the degree of efficiency with which the body uses excess dietary energy for fat storage is, to a considerable extent, inheri...

journal_title：Clinical neuropharmacology

authors： Van Itallie TB

更新日期：1988-01-01 00:00:00

abstract：OBJECTIVE:To describe an unusual case of camptocormia responding to levodopa. METHODS:We present a case of camptocormia with a sustained excellent response to levodopa in a patient with negative dopamine transporter and no DYT 5 genetic mutations. RESULTS:We present a 52-year-old man with 2 years' history of progress...

journal_title：Clinical neuropharmacology

authors： Oravivattanakul S,Abboud H,Fernandez H,Itin I

更新日期：2014-03-01 00:00:00

abstract：OBJECTIVES:Ponezumab is a humanized antiamyloid beta (Aβ) monoclonal antibody designed to treat Alzheimer disease (AD). METHODS:This randomized, double-blind, single-dose-escalation study evaluated the safety, pharmacokinetics, and pharmacodynamics of 0.1, 0.3, 1, 3, and 10 mg/kg ponezumab (n = 4, 4, 4, 6, and 8, resp...

journal_title：Clinical neuropharmacology

authors： Landen JW,Zhao Q,Cohen S,Borrie M,Woodward M,Billing CB Jr,Bales K,Alvey C,McCush F,Yang J,Kupiec JW,Bednar MM

更新日期：2013-01-01 00:00:00

abstract：OBJECTIVE:Psychogenic polydipsia occurs frequently in patients with chronic psychiatric illness and is often unmanageable. We herein report 5 patients in whom acetazolamide was trialed for this symptom. METHODS:We encountered a case in which polydipsia improved with incidental administration of acetazolamide. We then ...

journal_title：Clinical neuropharmacology

authors： Takagi S,Watanabe Y,Imaoka T,Sakata M,Watanabe M

更新日期：2011-01-01 00:00:00

abstract：OBJECTIVE:We present 3 new cases of psychotic symptoms in patients with adult attention-deficit/hyperactivity disorder while regularly treated with a stimulant therapy with methylphenidate. METHODS:Existing literature about this theme is reviewed, and potential mechanisms are discussed. RESULTS AND CONCLUSIONS:Medica...

journal_title：Clinical neuropharmacology

authors： Kraemer M,Uekermann J,Wiltfang J,Kis B

更新日期：2010-07-01 00:00:00

abstract：OBJECTIVES:Perampanel is a recently introduced antiepileptic drug (AED) with a unique action mechanism of noncompetitive and selective α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid antagonist. Because of delayed approval of perampanel in most Asian countries, there is limited information on the clinical usefulne...

journal_title：Clinical neuropharmacology

authors： Kim DW,Oh J

更新日期：2018-01-01 00:00:00

abstract：:Therapeutic strategies in the treatment of dystonia consist primarily of pharmacologic, surgical, and supportive approaches. Many recent advances have been made in the treatment of dystonia with newer medications, availability of different botulinum toxins, and surgical procedures. However, these treatment modalities ...

journal_title：Clinical neuropharmacology

authors： Goldman JG,Comella CL

更新日期：2003-03-01 00:00:00

abstract：:Neuroleptic-induced tardive dyskinesia (TD) that persists for 1 year or more following withdrawal of neuroleptics is usually said to be permanent. Early spontaneous remissions have been well described but most such remissions occurred within the first few months following neuroleptic withdrawal, and no published studi...

journal_title：Clinical neuropharmacology

authors： Klawans HL,Tanner CM,Barr A

更新日期：1984-01-01 00:00:00

abstract：:The effects of the psychotropic drug etoperidone on the response to laboratory stressors was investigated in a controlled study. Cardiovascular and hormonal (catecholamines, corticotropin, and cortisol) measurements were made in a group of young, healthy volunteers during a cold pressor test (CPT), a mental arithmetic...

journal_title：Clinical neuropharmacology

authors： Costa A,Martignoni E,Blandini F,Petraglia F,Genazzani AR,Nappi G

更新日期：1993-04-01 00:00:00

abstract：:Venlafaxine (VEN) pharmacokinetics and effects on the brain monoamine output were investigated in the context of experimental hepatic encephalopathy (HE). Systemic VEN (10 mg/kg; subcutaneous) was administered to chronic portacaval shunted (PCS) and sham-operated rats. Their neocortical extracellular levels of 5-HT, 5...

journal_title：Clinical neuropharmacology

authors： Wikell C,Bergqvist PB,Hjorth S,Apelqvist G,Björk H,Bengtsson F

更新日期：1998-09-01 00:00:00

abstract：:The suppressive roles of adrenergic stimulation and rapid eye movement (REM) sleep on human prolactin (PRL) secretion are controversial. We examined the effects of sleep, clonidine (an alpha 2-adrenergic agonist), and their interaction on PRL secretion. Two groups of normal men (nine each) were studied in two morning ...

journal_title：Clinical neuropharmacology

authors： Cavallo A,Carskadon MA,Grocer P

更新日期：1991-10-01 00:00:00

abstract：OBJECTIVE:The pathophysiology of hallucinations in Parkinson disease is poorly understood. This study investigated the relation between visual hallucination and visual evoked potentials (VEPs) in Parkinson disease. METHODS:Nineteen patients with Parkinson disease were studied. The authors divided patients into 2 group...

journal_title：Clinical neuropharmacology

authors： Matsui H,Udaka F,Tamura A,Oda M,Kubori T,Nishinaka K,Kameyama M

更新日期：2005-03-01 00:00:00

abstract：:This study was devised to check the feasibility and validity of a rating scale specifically designed to evaluate gait impairment in Parkinson's disease (RSGE). Demographic data, a brief questionnaire on general aspects influencing gait and mobility, a battery of scales (Barthel Index; Hoehn and Yahr staging; and North...

journal_title：Clinical neuropharmacology

authors： Martínez-Martín P,García Urra D,del Ser Quijano T,Balseiro Gómez J,Gómez Utrero E,Piñeiro R,Andrés MT

更新日期：1997-06-01 00:00:00

abstract：OBJECTIVE:A multicenter open-label clinical trial was conducted to evaluate the clinical usefulness of topiramate (TPM) as primary or adjunctive therapy for infantile spasms in the postmarketing period in China. METHODS:Thirty-four centers participated in the trial. Patients included in the study had 1 or more seizure...

journal_title：Clinical neuropharmacology

authors： Zou LP,Lin Q,Qin J,Cai FC,Liu ZS,Mix E,Topiramate Study Group.

更新日期：2008-03-01 00:00:00

abstract：OBJECTIVES:A number of research studies support the weight loss effects of metformin and topiramate for obese people with schizophrenia. However, only a few studies have addressed the sustainability of the body weight reduction after discontinuation of these drugs. Moreover, head-to-head studies are still lacking. The ...

journal_title：Clinical neuropharmacology

authors： Peng PJ,Ho PS,Tsai CK,Huang SY,Liang CS

更新日期：2016-11-01 00:00:00

abstract：:In recent studies, disorders of chromatic and achromatic vision in parkinsonian patients have been demonstrated; these could be partially restored after application of L-Dopa. In this study, the effect of a 3-day infusion therapy with amantadine sulphate on color vision was evaluated in 19 parkinsonian patients by use...

journal_title：Clinical neuropharmacology

authors： Büttner T,Kuhn W,Müller T,Patzold T,Przuntek H

更新日期：1995-10-01 00:00:00

abstract：:Several recent reports attest to zolpidem's strong potential for abuse, dependence, and severe withdrawal symptoms upon its discontinuation. We report, for the first time, on 1 case of heavy zolpidem abuse and dependence with severe withdrawal symptoms twice treated safely and successfully with pregabalin, a newer ant...

journal_title：Clinical neuropharmacology

authors： Oulis P,Nakkas G,Masdrakis VG

更新日期：2011-03-01 00:00:00

abstract：:Deprenyl, a selective inhibitor of monoamine oxidase, type B, which is free of the "tyramine effect," may ameliorate symptom fluctuations in advanced Parkinson's disease (PD). We randomized 96 patients with marked symptom fluctuations at three centers to receive either deprenyl 5 mg b.i.d. or placebo in parallel fashi...

journal_title：Clinical neuropharmacology

authors： Golbe LI,Lieberman AN,Muenter MD,Ahlskog JE,Gopinathan G,Neophytides AN,Foo SH,Duvoisin RC

更新日期：1988-02-01 00:00:00

abstract：BACKGROUND AND PURPOSE:Treatment of chronic insomnia with nightly hypnotics is efficacious, but discontinuation is recommended after 1 month, less than the average disease duration. This study was undertaken to determine the efficacy of intermittent administration. PATIENTS AND METHODS:A double-blind study was carried...

journal_title：Clinical neuropharmacology

authors： Parrino L,Smerieri A,Giglia F,Milioli G,De Paolis F,Terzano MG

更新日期：2008-01-01 00:00:00

abstract：OBJECTIVES:The high incidence of fibrotic cardiac valvulopathies reported in association with the 8beta-ergoline dopamine (DA) agonist, pergolide, and also case reports for cabergoline and bromocriptine have made it necessary to review the theoretical basis and actual findings in the case of another DA agonist, the 8al...

journal_title：Clinical neuropharmacology

authors： Hofmann C,Penner U,Dorow R,Pertz HH,Jähnichen S,Horowski R,Latté KP,Palla D,Schurad B

更新日期：2006-03-01 00:00:00

abstract：:The latency of P300 "cognitive" event-related potentials changes if cholinergic activities of the central nervous system are pharmacologically manipulated. We tested the hypothesis that the new cholinesterase inhibitors donepezil (DPZ) and rivastigmine (Riv) may have an effect on the frequently abnormal P300 component...

journal_title：Clinical neuropharmacology

authors： Thomas A,Iacono D,Bonanni L,D'Andreamatteo G,Onofrj M

更新日期：2001-01-01 00:00:00

abstract：:Clinical trials with cholinergic agents suggest that cholinergic hypertrophy may be beneficial in the treatment of Alzheimer's disease (AD). Recent findings substantiate the view that nerve growth factor (NGF) selectively acts on cholinergic neurons. In adult rats and primates, intraventricular administration of nerve...

journal_title：Clinical neuropharmacology

authors： Hefti F,Schneider LS

更新日期：1991-01-01 00:00:00

abstract：:Six males and one female with chronic tic disorders, whose ages ranged from 12 to 31 years, were evaluated before treatment, after 1 month on placebo, after a single 10 mg nifedipine dose (three patients), and monthly while on flunarizine 10-15 mg (mean dose of 13 mg). None of the patients receiving nifedipine improve...

journal_title：Clinical neuropharmacology

authors： Micheli F,Gatto M,Lekhuniec E,Mangone C,Fernandez Pardal M,Pikielny R,Casas Parera I

更新日期：1990-02-01 00:00:00